/

Atavistik Bio

  • What it is:Atavistik Bio is a privately-held biopharmaceutical company focused on discovering precision allosteric small molecules to treat metabolic diseases, cancer, and rare genetic diseases.
  • Rating:78/100Good
  • Expert's conclusion:Atavistik Bio has attracted a number of big-name biotech firms and investors who believe that its use of artificial intelligence to identify and develop cancer drugs that are highly specific to patients' genetic profiles is a good bet — albeit one requiring some time before it can be proved out.
Visit website
Reviewed byMaxim Manylov·Web3 Engineer & Serial Founder

What Is Atavistik Bio and What Does It Do?

Atavistik Bio is an innovative biotech company that has developed new ways to discover precision allosteric small molecules for treating metabolic diseases and cancers. Atavistik Bio has developed a proprietary drug discovery process that can identify non-obvious regulatory sites on disease-related proteins. It was co-founded by two of the world’s most respected scientists from the Howard Hughes Medical Institute (HHMI), Dr. Jared Rutter (University of Utah) and Dr. Ralph DeBerardinis (UT Southwestern). Atavistik Bio is headquartered in Cambridge, Massachusetts and focuses its research efforts on developing treatments for oncology and rare diseases and has a number of promising compounds in the preclinical development phase.

Active
📍Cambridge, MA
📅Founded 2021
🏢Private
TARGET SEGMENTS
PharmaBiotechOncologyRare DiseasesMetabolic Diseases

What Are Atavistik Bio's Key Business Metrics?

📊
$100M
Total Funding
📊
$40M Series B
Latest Funding Round
📊
$60M
Series A Funding
📊
6+ preclinical
Pipeline Programs
📊
2021
Founding Year

How Credible and Trustworthy Is Atavistik Bio?

78/100
Good

Early stage biotech company with well-funded growth, good experience-based leadership and successful exit history; however, the company has limited publicly available information regarding its products and customer/user reviews.

BREAKDOWN
Product Maturity60/100
Company Stability85/100
Security & Compliance70/100
User Reviews50/100
Transparency75/100
Support Quality65/100
TRUST SIGNALS
$100M total funding raisedLeadership from Peloton (acquired by Merck for $1.1B) and Blueprint MedicinesCo-founded by HHMI investigatorsPartnership with Plex Research

What is the history of Atavistik Bio and its key milestones?

2021

Company Founded

Founded by HHMI researchers Dr. Jared Rutter (University of Utah) and Dr. Ralph DeBerardinis (UT Southwestern) to develop allosteric small molecule drugs as a treatment for various diseases.

2024

Series A Funding

Completed a $60 million series A round of financing to further validate its genetically identified targets in metabolic diseases and cancer.

2025

Series B Funding

Received an additional $40 million in a Series B round of financing bringing the total amount raised to $100 million.

2023

Plex Research Partnership

Announces a partnership with Plex Research to integrate its AI technology platform with Atavistik Bio’s metabolite protein screening platform.

What Are the Key Features of Atavistik Bio?

🏛️
Allosteric Binding Pocket Identification
Atavistik Bio uses a proprietary platform based upon evolutionary biology to identify non-obvious regulatory sites on disease-related proteins.
✨
Precision Small Molecule Design
Atavistik Bio designs allosteric small molecules that modulate the function of proteins at sites on the proteins that are outside the active site, which provides greater specificity for potential therapeutic applications.
✨
Genetically Validated Targets
Atavistik Bio has focused its research on targets identified through human genetic studies because these targets have a higher likelihood of being effective in the treatment of oncology and metabolic diseases.
✨
AI-Enhanced Screening
Atavistik Bio plans to use Plex Research’s AI platform in conjunction with its proprietary metabolite protein screening platform to find novel targets for drug development.
✨
Multi-Disease Pipeline Coverage
Atavistik Bio is addressing precision oncology, rare diseases and metabolic disorders, including AKT1 mutation-positive solid tumors and myeloproliferative neoplasms. The following text has been rewritten to make it sound more natural and conversational: BEGIN_TEXT

What Technology Stack and Infrastructure Does Atavistik Bio Use?

Integrations

Plex Research AI platform

AI/ML Capabilities

Proprietary drug discovery platform integrating AI-based search engine from Plex Research partnership with metabolite-protein screening technology, powered by evolutionary biology principles for allosteric site identification.

Limited technical details available; AI integration confirmed via partnership announcement, core platform based on scientific founders' biochemistry expertise.

What Are the Best Use Cases for Atavistik Bio?

Oncology Drug Discovery Teams
The company will develop new allosteric drug modulators for cancer targets such as the genetic mutation AKT1 E17K and myeloproliferative neoplasms.
Rare Disease Specialists
The company will create targeted treatments for rare diseases (vascular malformations, HHT, hepatic encephalopathy) by accessing previously unexplored binding sites.
Metabolic Disease Researchers
The company will use an evolutionary inspired platform to discover small molecules that regulate metabolic pathways and can be used in the treatment of endocrine and metabolic disorders.
Biopharma Partnerships
The company will provide an AI enhanced screening platform for collaborative target identification in both oncology and rare disease pipeline development.
NOT FORGeneric Small Molecule Programs
Not recommended - the company has a specialized focus on developing precision drugs through the modulation of protein function via allosteric mechanisms, rather than the inhibition of orthosteric or broad-spectrum drug targets.
NOT FORClinical-Stage Programs
The company's preclinical discovery focus does not lend itself well to companies that require early stage clinical candidates.

What APIs and Integrations Does Atavistik Bio Support?

API Type
No public API available. Atavistik Bio is a clinical-stage biotech focused on internal drug discovery using proprietary AMPS platform with AI integration
Authentication
Not applicable - no developer API or public integration options disclosed
Webhooks
No webhook support. Platform designed for proprietary research collaborations (e.g., Pfizer), not external developer access
SDKs
No official SDKs available. No GitHub repositories or developer tools found
Documentation
No API documentation. Company website focuses on science, pipeline, and partnerships, no developer portal
Sandbox
No sandbox or testing environment for external users
SLA
No public SLA. Collaborations with pharma partners like Pfizer under confidential terms
Rate Limits
Not applicable
Use Cases
Internal use only: AI-enabled structure-based drug discovery for allosteric small molecules. Partner collaborations for target discovery (e.g., oncology targets with Pfizer)

What Are Common Questions About Atavistik Bio?

AMPS is Atavistik Bio’s proprietary platform that uses artificial intelligence to integrate experimental and computational techniques to predict and identify hidden or “cryptic” allosteric binding sites on proteins. Using this technology, Atavistik is able to develop highly selective small molecule therapeutics for difficult-to-drug protein targets, such as the AKT1 mutations found in some patients with certain types of solid tumor cancers and JAK2 V617F found in some patients with myeloproliferative neoplasms.

ATV-1601 is a first-in-class selective allosteric AKT1 E17K inhibitor for solid tumors, particularly those affecting the breast, endometrium, and prostate glands. The first patient was enrolled in a Phase I clinical study evaluating safety, tolerability, and efficacy when administered as a single agent or in combination with fulvestrant.

Atavistik develops precision allosteric therapeutics to treat disease-causing mutations in genes with AI enabled structural-based design. Allosteric drugs are more specific than pan-inhibitors allowing for higher efficacy and lower toxicity while addressing oncogenic mutations that have failed to respond to traditional chemotherapy agents.

Atavistik is a biotechnology company focused on oncology and rare diseases and utilizes standard practices within the industry for protecting intellectual property rights in its collaborations. No particular security certifications were reported by the company, however, at least two partnership agreements with Pfizer indicate the company maintains enterprise level security protocols related to the handling of data.

Atavistik received $120 million in Series B funding from Nextech Invest and The Column Group and also an additional $40 million. Other investors that have invested in Atavistik are Lux Capital and Regeneron Ventures to help advance HHT and MPN programs.

There is no public or free trial available. The AMPS Platform is owned by Atavistik as it is used for their internal pipeline and for their pharmaceutical partners such as Pfizer.

Oncology (Phase 1 of AKT1 E17K solid tumors using ATV-1601), HHT (AKT1-selective inhibitor), and MPNs (JAK2 V617F inhibitor). Precision allosteric small molecules are the focus of Atavistik.

Pfizer (for undisclosed targets in Oncology) and Plex Research (to enhance AI informatics capabilities). Validating the AMPS Platform for allosteric binder discovery, as both collaborations will do.

Is Atavistik Bio Worth It?

Atavistik Bio is an emerging clinical-stage biotech that utilizes its proprietary AI-based AMPS platform to create precision allosteric small-molecule therapeutics for cancer and rare diseases. With multiple Phase 1 trials currently underway, along with major investments totaling over $160 million, and partnership agreements including those with Pfizer, there is substantial validation of Atavistik Bio's business model; however, similar to other biotech companies, Atavistik Bio is at risk due to potential clinical failures.

Recommended For

  • Pharmaceutical companies looking for new allosteric modulators for difficult to target areas.
  • Oncology investors who are looking for mutation-selective precision therapeutics.
  • Specialists in rare disease treatment that can treat HHT and MPNs.
  • Enthusiasts of AI drug discovery who are monitoring the integration of computational and experimental methods.

!
Use With Caution

  • Commercial product based organizations that require products quickly - they are too far along in their clinical trials.
  • Risk adverse investors - they will need to wait for Phase 1 results from ATV-1601 to determine if investing in Atavistik Bio will be successful.
  • Organizations that require broad-spectrum inhibitors rather than mutant-selective.

Not Recommended For

  • Teams that require a ready-to-go AI-based drug discovery platform or API.
  • Biotechnology firms that cannot partner with larger biopharmaceutical firms for co-development.
  • General users of automation technology - the focus of Atavistik Bio is solely on the discovery of therapeutics.
Expert's Conclusion

Atavistik Bio has attracted a number of big-name biotech firms and investors who believe that its use of artificial intelligence to identify and develop cancer drugs that are highly specific to patients' genetic profiles is a good bet — albeit one requiring some time before it can be proved out.

Best For
Pharmaceutical companies looking for new allosteric modulators for difficult to target areas.Oncology investors who are looking for mutation-selective precision therapeutics.Specialists in rare disease treatment that can treat HHT and MPNs.

What do expert reviews and research say about Atavistik Bio?

Key Findings

Atavistik is moving forward with an integrated AI/AMPS (Allosteric Molecular Pocket Solution) platform that is being used to create allosteric therapeutics that target AKT1 mutations (for which Phase 1 studies have already begun on ATV-1601); HHT (hereditary hemorrhagic telangiectasia); and myeloproliferative neoplasms (MPNs).

Data Quality

Good - detailed pipeline and funding info from press releases and company site. Clinical trial specifics public (NCT07038369); limited insights on internal operations, pricing, or roadmap as typical for private clinical-stage biotech.

Risk Factors

!
As part of a $120 million Series B funding round, as well as a $40 million follow-on investment from a group of top-tier investors, Atavistik has entered into a partnership agreement with Pfizer to utilize its AMPS platform to identify allosteric modulators for two undisclosed targets.
!
In addition, Atavistic has partnered with Plex Research to expand its use of AI in both informatics and the development of interactomes.
!
The Company's emerging pipeline offers solutions to several unmet needs in the field of precision oncology that offer better selectivity than pan-inhibitors do.
!
Early clinical-stage – Phase 1 data pending for lead compound ATV-1601.
Last updated: February 2026

What Additional Information Is Available for Atavistik Bio?

Key Partnerships

Risk associated with executing biotechnology projects in the areas of oncology and rare disease trials.

Recent Funding

Increasing competition in the area of drug discovery based on allosterics and AI.

Pipeline Highlights

Privately held – therefore, limited visibility in terms of the financial performance of the Company.

Leadership

In addition to its collaboration with Pfizer to find allosteric therapeutics for two unidentified targets using the AMPS platform, Pfizer also has an option to license the rights to those compounds. Additionally, Atavistic is working with Plex Research to improve its ability to perform AI powered informatics and interatome mapping.

Technology Platform

Atavistik received $120 million in funding for its Series B round from Nextech Invest and The Column Group, as well as investments from existing investors including Lux Capital and new investor Regeneron Ventures. An additional $40 million was invested to move the HHT and MPN programs toward clinical proof-of-concept. The following is a list of competitive AI Biotech companies that use artificial intelligence to find drugs, as well as how they are different from Atavistik.

What Are the Best Alternatives to Atavistik Bio?

  • •
    Recursion Pharmaceuticals: Recursion Pharmaceuticals – An AI-NATIVE Drug Discovery Platform that Maps Biology-Disease Relationships for Novel Targets. Recursion has a broader disease focus than Atavistik’s allosteric precision oncology and has multiple Phase 2 Assets. For an investor looking for diversified AI Biotech pipelines, this could be the best fit. (Recursion.com)
  • •
    Schrödinger: Schrödinger – A physics-based computational platform for the design of small molecules, including those targeting allosteric sites. Schrödinger is more mature with partner programs and revenue-generating products than Atavistik’s clinical stage focus on precision oncology. For computational chemistry teams that need enterprise software, this could be the best option. (Schrödinger.com)
  • •
    XtalPi: XtalPi – Uses AI-DRIVEN drug discovery with integrated robotics for crystallization and synthesis. XtalPi has strong crystal structure prediction capability in addition to its ability to discover novel allosteric binding sites. For an investor interested in partnerships with Asian companies or accelerating their entire discovery process from start to finish, this may be the best fit. (Xtalpi.com)
  • •
    Insilico Medicine: Insilico Medicine – Uses generative AI to identify novel targets for small molecule therapy and also to design those small molecules. First AI-discovered molecule in phase II trials. In terms of speed, Insilico’s de novo design is faster than Atavistik’s structure-based allostery. For an investor interested in exploring therapeutics broadly outside of oncology mutations, this may be the best fit. (Insilico.com)
  • •
    AbCellera: AbCellera – Uses AI-POWERED antibody discovery to create a massive preclinical pipeline of antibodies. For an investor interested in developing biologic therapies using precision medicine, AbCellera is an alternative modality to Atavistik’s small molecules and has a proven partnership model with pharmaceutical companies. (Abcellera.com)

Scientific ROI Metrics

Rapid discovery of functional cryptic pockets validated binders
Precision Allosteric Hit Identification
HHT program to clinic H1 2026 milestones
Pipeline Advancement
160 million USD
Funding Raised for Clinical POC
AKT1, JAK2 V617F, undisclosed Pfizer targets precision therapeutics
Target Classes Unlocked

Core Discovery Capabilities

Cryptic Allosteric Pocket Detection

AMPS (Allosteric Modulator Prediction Suite), a proprietary AI platform identifies functional allosteric binding pockets in challenging protein targets.

AI-Enabled Structure-Based Design

Proprietary AI drug discovery engine designs small molecules to bind to novel allosteric sites.

Precision Mutant-Selective Inhibition

Selective inhibitors for AKT1 (for HHT) and JAK2 V617F (for MPN).

Integrated Computational-Experimental Workflow

Integrates proprietary computational and experimental techniques for hit-to-lead optimization.

Interactome Mapping Enhancement

Partners with Plex Research to enhance AI/Informatics capabilities.

ML Architecture & Computational Specifications

Core Platform
AMPS™ (Allosteric Modulation Platform System)
AI Capabilities
Proprietary AI-enabled structure-based drug discovery engine
Target Discovery Approach
Cryptic allosteric pocket identification across target classes
Molecular Design
Precision small molecule therapeutics for disease-driving mutations
Validation Method
Integrated computational and experimental techniques
Informatics Enhancement
Plex Research AI-powered Interactome mapping
Deployment Model
Proprietary platform with pharma partnerships (Pfizer)

What Primary Use Cases Does Atavistik Bio Offer?

Cryptic Allosteric Pocket DiscoveryPrecision Mutant-Selective InhibitorsRare Disease Therapeutics (HHT)Oncology Precision Medicine (MPNs)Pharma Partnership Target ValidationAI-Structure Based Drug DesignIND-Enabling Precision Oncology

What Is Atavistik Bio's Regulatory Compliance Requirements Status?

IND-Enabling StudiesPrecision oncology program entering clinic H1 2026
Clinical Proof-of-Concept Funding$120M Series B secured for HHT/MPN programs
Pharma Partnership ValidationPfizer collaboration for undisclosed targets
Proprietary Platform IP ProtectionAMPS™ platform exclusively licensed programs
Computational Model ValidationBig pharma validation through partnerships

Integration & Workflow Capabilities

Pharma Partnership Integration

Partnered with Pfizer for target selection and licensing options.

AI-Informatics Collaboration

Integrating with Plex Research for enhanced Interactome mapping capabilities.

Computational-Experimental Pipeline

Provides end-to-end services from identifying novel allosteric binding site to IND-enabling studies.

Precision Allostery Workflow

Unlocks "cryptic" allosteric binding pockets to translate into clinical candidates.

AI Drug Discovery Platform Performance Benchmarks

Performance MetricAtavistik AMPS™ PlatformTraditional MethodsStatus
Cryptic Pocket DiscoveryFunctional allosteric binders identifiedHistorically difficult featValidated by Pfizer partnership
Precision Mutant InhibitionAKT1-selective, JAK2 V617F-selectiveNon-selective inhibitorsDisease-modifying potential
Rare Disease Pipeline SpeedHHT program to clinic H1 2026Years of traditional discoveryAccelerated timeline
Funding Validation$160M raised (Series B + extension)Investor confidence
Target TractabilityChallenging/intractable targetsLimited optionsNovel therapeutic opportunities

AI Drug Discovery Platform Evaluation Priority Matrix

Priority LevelEvaluation CategoryAtavistik Bio Assessment
1 - CRITICALScientific Impact & ValidationPfizer partnership validates AMPS™ for challenging targets; precision oncology to clinic 2026
1 - CRITICALROI Metrics & Timeline Reduction$160M funding; HHT program accelerated to H1 2026 clinic entry
2 - HIGHML Explainability & InterpretabilityProprietary AI validated through big pharma collaboration
2 - HIGHR&D Integration & WorkflowSeamless pharma partnerships; Plex Research informatics integration
3 - MEDIUMComputational ScalabilityPlatform validated across AKT1, JAK2, Pfizer targets
3 - MEDIUMRegulatory & Compliance ReadinessIND-enabling activities underway for lead program

Expert Reviews

📝

No reviews yet

Be the first to review Atavistik Bio!

Write a Review

Similar Products

PostEra
postera.ai
BenevolentAI
benevolent.ai
Recursion Pharmaceuticals
recursion.com